Systemic light chain (AL) amyloidosis is a clonal plasma cell disorder characterized by the deposition of immunoglobulin light chain-associated amyloid material in various organs 1 . While therapies such as high-dose melphalan followed by autologous stem cell transplantation (ASCT) can result in deep and durable responses 2 , only approximately a quarter of newly diagnosed patients are deemed transplant eligible 1 , 3 . Even with successful initial therapy, relapses occur, and not infrequently the response is of insufficient depth to protect against further amyloid deposits in vital organs. Alternative therapeutic options are required for such patients.
No takes yet. Share an insight, caveat, or question.
Sidiqi et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: